RxDoctor Payments Data

Marina Iskandir, MD

Interventional Cardiology · Brooklyn, NYNPI 1487069811

Payments from drug & device makers

$2,213in general payments, 2019–2025

Across 104 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$426
  • Abiomed$344
  • Novartis$222
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$207
  • Abbott$187
  • Shockwave Medical, Inc$165
  • plus $662 from 11 others

What the payments were for

  • Food & beverage$2,19999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,213 in reported general payments places this provider in the 15th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$95,718
Medicare patients
335
Services billed
887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan99$110,200
EliquisApixaban66$60,066
JardianceEmpagliflozin32$42,920
MounjaroTirzepatide14$17,336
OzempicSemaglutide18$17,098
BrilintaTicagrelor16$13,943
Praluent PenAlirocumab23$13,169
Repatha SureclickEvolocumab18$11,014
Repatha SyringeEvolocumab13$3,796
Potassium Chloride59$2,946
Torsemide69$2,152
Rosuvastatin Calcium129$1,550
Metoprolol Succinate135$1,496
Carvedilol148$1,331
Nebivolol Hcl36$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$222$110,20099 claims
Novo NordiskOzempic$79$17,09818 claims
AstraZenecaBrilinta$88$13,94316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →